Cytokinetics (CYTK) Projected to Post Earnings on Thursday

Cytokinetics (NASDAQ:CYTK - Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Cytokinetics to post earnings of ($1.29) per share and revenue of $14.26 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Cytokinetics Stock Performance

Shares of NASDAQ:CYTK traded down $0.86 during midday trading on Friday, reaching $50.26. The company's stock had a trading volume of 2,169,437 shares, compared to its average volume of 1,607,616. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The stock has a fifty day moving average of $47.29 and a 200 day moving average of $51.53. Cytokinetics has a twelve month low of $40.53 and a twelve month high of $81.36. The firm has a market capitalization of $5.93 billion, a PE ratio of -9.34 and a beta of 0.83.

Analysts Set New Price Targets

Several brokerages have weighed in on CYTK. JMP Securities reaffirmed a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Royal Bank of Canada raised their target price on Cytokinetics from $80.00 to $82.00 and gave the stock an "outperform" rating in a report on Wednesday, December 18th. HC Wainwright reiterated a "buy" rating and set a $120.00 price target on shares of Cytokinetics in a research report on Tuesday, January 21st. Evercore ISI upgraded Cytokinetics to a "strong-buy" rating in a research report on Friday, February 7th. Finally, Mizuho lifted their target price on shares of Cytokinetics from $99.00 to $103.00 and gave the company an "outperform" rating in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Cytokinetics has an average rating of "Moderate Buy" and a consensus price target of $82.00.

Insider Buying and Selling

In related news, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total value of $91,960.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company's stock, valued at approximately $5,336,944.58. This represents a 1.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Wendall Wierenga sold 742 shares of the company's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $48.61, for a total transaction of $36,068.62. Following the sale, the director now directly owns 24,559 shares of the company's stock, valued at $1,193,812.99. The trade was a 2.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,122 shares of company stock worth $1,494,016 in the last 90 days. Insiders own 3.40% of the company's stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.